On Friday, Veeva Systems Inc. (NYSE:VEEV) shares received an optimistic outlook from Piper Sandler, with the investment firm raising its price target on the stock to $280 from $230, while reiterating an Overweight rating. The adjustment follows Veeva's recent analyst session where the company set a $6 billion revenue goal for calendar year 2030, indicating strong growth ambitions in the life sciences sector.
The analyst from Piper Sandler highlighted Veeva's potential to expand its reach within the over $2 trillion life sciences industry, suggesting that the company's R&D products could see a compound annual growth rate (CAGR) of 17%, potentially tripling to $4 billion. This projection comes despite a more conservative 7% CAGR forecast for Veeva's Commercial (CRM) products, which already hold a dominant market share of over 80%.
Veeva's reaffirmation of a target operating margin above 35% was also noted as a significant positive signal, mirroring a similar margin goal set in 2019 that Veeva managed to exceed, achieving an average operating margin of 38.5% over the past five years. This consistency in maintaining a strong margin profile was cited as a "margin floor" by the analyst.
In light of these factors, Piper Sandler has increased its top-line estimates for the next year, anticipating a rise in the adoption of Veeva's R&D solutions. The new stock price target is based on an enterprise value to free cash flow (EV/FCF) multiple of 25 times the estimated free cash flow for calendar year 2029, which remains consistent with previous valuation methodologies used by the firm.
In other recent news, Veeva Systems has reported a 15% year-over-year increase in total revenue, reaching $676.2 million, along with an earnings per share of $1.62. The company has also formed a strategic partnership with Walgreens, aiming to enhance patient outcomes through the use of Veeva's Data Cloud products and services.
Analyst firms Oppenheimer, Baird, and Barclays (LON:BARC) have provided recent assessments of Veeva. Oppenheimer reaffirmed an Outperform rating, maintaining a price target of $230.00, while Baird maintained an Outperform rating but reduced the price target from $251.00 to $245.00 due to concerns over research and development spending patterns. Barclays reiterated an Overweight rating with a steady price target of $240.00.
In other developments, Veeva welcomed Brian Van Wagener as their new Chief Financial Officer and expanded its clinical trial platform, Veeva Site Connect. The company also anticipates wider adoption of its Compass and EDC products in the long term, as outlined by a prominent Salesforce (NYSE:CRM) Summit integrator and Veeva partner. These are among the recent developments concerning Veeva Systems.
InvestingPro Insights
Veeva Systems Inc.'s strong market position and growth prospects, as highlighted in the article, are further supported by recent data from InvestingPro. The company's market capitalization stands at $36.17 billion, reflecting its significant presence in the life sciences technology sector. Veeva's revenue growth of 15.29% over the last twelve months aligns with the analyst's positive outlook on the company's expansion potential.
InvestingPro Tips indicate that Veeva holds more cash than debt on its balance sheet, which could provide financial flexibility to support its ambitious growth plans. Additionally, the company's strong return over the last three months, with a price total return of 20.45%, suggests investor confidence in Veeva's strategy and market position.
It's worth noting that Veeva is trading at a high P/E ratio of 58.53, which may reflect the market's high expectations for future growth. This aligns with the company's $6 billion revenue goal for 2030 mentioned in the article. Investors interested in a deeper analysis can find 13 additional InvestingPro Tips for Veeva Systems, offering further insights into the company's financial health and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.